EF
NUVB icon

Entrust Financial’s Nuvation Bio NUVB Stock Holding History

Entrust Financial’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$909 Buy
+160
New +$782 ﹤0.01% 429

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Entrust Financial's NUVB Position: Q2 2026 in Review

Entrust Financial opened a new position in Nuvation Bio (NUVB) in Q2 2026: 160 shares worth $909. The stake represents ﹤0.01% of the portfolio and ranks #429 among its holdings.

243 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Entrust Financial held 160 shares of Nuvation Bio worth $909 as of Q2 2026.
  • Nuvation Bio was a new Entrust Financial position in Q2 2026.
  • Nuvation Bio made up ﹤0.01% of Entrust Financial's portfolio in Q2 2026, its #429 holding.
  • 243 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Entrust Financial's 13F filing for Q2 2026, filed 20 Jul 2026.